首页LSTA • NASDAQ
add
Lisata Therapeutics Inc
昨日收盘价
$1.97
当日价格范围
$1.92 - $2.00
年度波幅
$1.81 - $4.20
市值
1720.04万 USD
平均交易量
10.63万
市盈率
-
股息率
-
主要交易所
NASDAQ
市场资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
收入 | — | — |
经营支出 | 441.40万 | -17.28% |
净收入 | -424.90万 | 13.81% |
净利润率 | — | — |
每股收益 | -0.49 | 16.95% |
息税折旧摊销前利润 | -437.00万 | 17.45% |
有效税率 | — | — |
资产负债表
总资产
负债总额
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1899.80万 | -47.02% |
总资产 | 2175.90万 | -43.04% |
负债总额 | 464.00万 | -2.58% |
权益总额 | 1711.90万 | — |
发行在外的股份 | 882.07万 | — |
市净率 | 0.99 | — |
资产回报率 | -47.04% | — |
资本回报率 | -58.17% | — |
现金流
现金净变动
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
净收入 | -424.90万 | 13.81% |
来自运营的现金 | -334.20万 | -32.72% |
投资现金 | 515.00万 | 181.68% |
融资现金 | 35.30万 | — |
现金净变动 | 216.30万 | 124.62% |
自由现金流 | -184.28万 | -115.02% |
简介
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022.
In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
成立时间
1980
员工数量
26
